General Information of This Metabolic Reaction (MR) (ID: MR010609)
Formula
SVG example
Unclear
Reactant N-0923 Product N-0923 Metabolite M12
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010612 N-0923 N-0923 Metabolite M10 Unclear - Unclear N-0923 [1]
MR010603 N-0923 N-0923 Metabolite M331 Unclear - Unclear N-0923 [1]
MR010597 N-0923 N-0923 Metabolite M4 Unclear - Unclear N-0923 [1]
MR010611 N-0923 N-0923 Metabolite M9 Unclear - Unclear N-0923 [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009255 Neupro N-despropyl-rotigotine Unclear - Unclear Neupro [2], [3]
MR009594 Rotigotine N-despropyl-rotigotine Unclear - Unclear Rotigotine [2]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010610 N-0923 Metabolite M12 N-0923 Metabolite M13 Unclear - Unclear N-0923 [1]
MR009596 N-despropyl-rotigotine N-Despropyl rotigotine glucuronide Conjugation - Glucuronidation Rotigotine [2]
MR009595 N-despropyl-rotigotine N-Despropyl rotigotine sulfate Oxidation - Sulfonation Rotigotine [2]
MR009256 N-despropyl-rotigotine Neupro Metabolite M1 Unclear - Unclear Neupro [2]
MR009257 N-despropyl-rotigotine Neupro Metabolite M2 Unclear - Unclear Neupro [2], [3]
References
1 Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry
2 Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
3 No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.